- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Gaithersburg Today
By the People, for the People
Capital International Investors Buys 100,284 Shares in GeneDx Holdings Corp.
The institutional investor now owns 0.35% of the genomic testing company.
Mar. 13, 2026 at 8:07am
Got story updates? Submit your updates here. ›
Capital International Investors acquired a new position in GeneDx Holdings Corp. (NASDAQ:WGS) during the 3rd quarter, according to a recent SEC filing. The institutional investor purchased 100,284 shares of the company's stock, valued at approximately $10,805,000.
Why it matters
GeneDx is a leading provider of comprehensive genetic and genomic testing services, specializing in rare and inherited disorders. The acquisition of a significant stake by a major institutional investor like Capital International Investors suggests confidence in the company's growth potential and market position.
The details
According to the filing, Capital International Investors now owns 0.35% of GeneDx's outstanding shares. The purchase comes as GeneDx continues to expand its portfolio of genetic testing services and grow its customer base among healthcare providers.
- The shares were acquired during the 3rd quarter of the company's fiscal year.
The players
Capital International Investors
An institutional investment firm that manages a global portfolio of equities.
GeneDx Holdings Corp.
A clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders.
The takeaway
The investment by Capital International Investors underscores the growing importance of genetic testing in healthcare and the potential for companies like GeneDx to capitalize on this trend. The acquisition could signal increased institutional interest and support for GeneDx as it continues to expand its reach and impact in the genomics space.
